BioNexus Gene Lab Corp Common stock (BGLC)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach BioNexus as a Graham-style asset buyer, but the numbers warn me away from calling it a bargain. The company sells industrial chemical raw materials and genomic screening, yet scale is tiny: market cap $3.9M and 19 employees. Revenue has collapsed. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was only $76,156, with a net loss of $286,451 and diluted EPS of -$0.12. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $22,842 and net loss $543,575. A year earlier, fiscal Q2 2025, the quarter ended 2025-06-30, revenue was $2.3M, so the latest quarter is a fraction of that. Annual filed figures show FY2025 revenue $7.4M and net loss $3.0M; FY2024 revenue $9.5M and net loss $1.6M; FY2023 revenue $9.8M and net loss $2.6M. That is not a moat; it is a shrinking business with persistent losses. The Lynch category is none because it has lost money in each of the last four years. Financial health has one bright spot: D/E 0.04, so debt is low. But FairStock calculations at the 2026-10-13 close show P/B 0.41 and P/E -1.05, ROE -33.66%, ROCE -18.99%, FCF yield -22.0%, Piotroski 5/9, Altman Z 1.75, and FairStock Score 37/100. The price is below book, but book value can evaporate through cash burn. With trailing free cash flow of -$853,600 and latest-quarter net margin -376.14%, the company needs revenue recovery and cost control to justify even its modest market value. I see speculative optionality, not investment quality. Without a path to durable profit, the low price is a warning, not a margin of safety.

In plain English: BioNexus sells chemical raw materials for industrial products and also offers genomic screening services. The business looks weak: it is losing money, sales have shrunk sharply, and it has not had a profitable year in the last four years. At $1.32 a share, the price is below the company's accounting value, but ongoing losses and cash burn make it hard to call a safe bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer